Patient Blood Management: An Internist's Perspective.
- Author:
Jieun UHM
1
Author Information
- Publication Type:Review
- Keywords: Transfusion; Iron; Erythropoietin; Chemotherapy-induced anemia; Anemia of renal disease
- MeSH: Acute Coronary Syndrome; Anemia; Blood Transfusion; Drug Labeling; Erythrocytes; Erythropoietin; Heart Failure; Humans; Iron; Mortality; Perioperative Care; Renal Insufficiency, Chronic; Risk Factors; United States Food and Drug Administration
- From:Hanyang Medical Reviews 2018;38(1):38-48
- CountryRepublic of Korea
- Language:English
- Abstract: Patient blood management (PBM) is an evidence-based, patient-focused approach to optimize the management of patient and blood transfusion. While PBM is relatively well established in perioperative care, it is not as well established in the medical field. Since anemia in medical patients is heterogeneous and complex in its pathogenesis, the evidence for the threshold of hemoglobin for red blood cell (RBC) transfusion and the use of erythropoiesis-stimulating agents (ESAs) is not strong. While anemia seems to be an adverse risk factor for mortality, it is uncertain if rapid correction of anemia through RBC transfusion can reverse the negative impact of anemia on clinical outcomes. The introduction of ESA is a breakthrough in reducing RBC transfusion and managing anemic patients with renal disease and cancer. Despite promising results from early trials, the United States Food and Drug Administration issued a black box warning for ESAs in 2007 because of concerns about higher mortality, serious cardiovascular and thromboembolic events, and tumor progression. Therefore, the individualized approach to each patient with anemia is recommended in various medical conditions such as acute coronary syndrome, heart failure, chronic kidney disease, and malignancies.
